This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay D is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Chieffo, R., Ferrari, F., Battista, P., Houdayer, E., Nuara, A., Alemanno, F., & Leocani, L. (2013). Neurorehabilitation and neural repair, 1545968313508471.
This study was designed to examine the effect of different stimulation frequencies on the inability to use spoken language due to a stroke-induced brain lesion. Patients were tested for their ability to correctly name a picture following either high, low, or sham stimulation. This study demonstrated that acute, high-frequency, brain stimulation using Brainsway® Deep TMS, or Deep Transcranial Magnetic Stimulation, significantly improves stroke-induced inability to use spoken language.